Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.
Parkinson's disease and multiple system atrophy are both characterised by the pathological accumulation of misfolded α-synuclein protein (thereby, both conditions are referred to as ...